Dr. Alan Shackelford gained national attention for his breakthrough treatment of a young patient with Dravet Syndrome. The child went from having approximately 300 intractable seizures per week to only a few after Dr. Shackelford prescribed a cannabinoid-based treatment. That moment went on to become a national news story in 2013. Since that story broke, Dr. Shackelford has never stopped treating patients and continues to prescribe cannabinoid-based treatments for a wide range of conditions that pose significant unmet medical needs.
By documenting what worked and what didn’t over the last 13 years, including both efficacy and safety information, Dr. Shackelford created a database of real-world experience with well over 25,000 patient interactions.
Shackelford Pharma was founded because of Dr. Shackelford’s pioneering spirit and determination to help patients who have largely been refractory to or intolerant of available prescription medicines. Those significant unmet medical needs motivated Dr. Shackelford to persevere when he saw improvement, even in the face of potential and actual criticism.
The database is what makes Shackelford Pharma truly unique, and it has attracted a world-class team of entrepreneurs, scientists, physicians, and pharmaceutical executives who are excited to analyze the data to develop new medicines for those with high unmet medical needs.
The company's lead drug candidate, SP1707, is supported by hundreds of patient treatment years of real-world data as well as data from preclinical animal studies.
Invest in Shackelford
Shackelford Pharma’s Regulation A Financing is now open. Investors are required to fill out the form below to begin the investment process.
Please check your JUNK/SPAM email folder if your invitation email from Dealmaker/Shackelford does not arrive in your inbox.